deucravacitinib,apremilast
BMS,amgen
['deucra']
wcd 2023 day 4 morning - pasi reductions for an oral tyk2 inhibitor dr. ronald b. vender reviews a poster about the tyk2 inhibitor deucravacitinib 
Up-to-date clinical news for dermatology. Publishers of The Chronicle of Skin & Allergy, The Chronicle of Cosmetic Medicine & Surgery, & Skin Spectrum Summit